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Available online 14 January 2016A paradigm shift from current population based medicine to personalized and participative medicine is under-
way. This transition is being supported by the development of clinical decision support systems based on predic-
tion models of treatment outcome. In radiation oncology, these models ‘learn’ using advanced and innovative
information technologies (ideally in a distributed fashion — please watch the animation: http://youtu.be/
ZDJFOxpwqEA) from all available/appropriate medical data (clinical, treatment, imaging, biological/genetic,
etc.) to achieve the highest possible accuracywith respect to prediction of tumor response and normal tissue tox-
icity. In this position paper, we deliver an overview of the factors that are associated with outcome in radiation
oncology and discuss the methodology behind the development of accurate prediction models, which is a multi-
faceted process. Subsequent to initial development/validation and clinical introduction, decision support systems
should be constantly re-evaluated (through quality assurance procedures) in different patient datasets in order to
reﬁne and re-optimize the models, ensuring the continuous utility of the models. In the reasonably near future,
decision support systemswill be fully integratedwithin the clinic, with data and knowledge being shared in a stan-
dardized, dynamic, and potentially global manner enabling truly personalized and participative medicine.
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Several major advances in cancer care (including radiation on-
cology) have been made in the last 5–10 years, with many new di-
agnostic techniques and treatment modalities becoming available
[1]. This wealth of choice, however, has brought with it new chal-
lenges. Attaining level I evidence is increasingly difﬁcult given the
copious disease, patient and treatment parameters that exist,
resulting in ever-increasing data heterogeneity [2]. This new reali-
ty is somewhat at odds with traditional evidence based medicine,
whereby randomized trials are designed for large populations of
homogenous patients. Consequently, new approaches are required
to build evidence for clinical decision making based upon this
wealth of patient, disease and treatment characteristics [3].
The challenge can be exempliﬁed as follows: For each patient, the
physiciansmust consider biology (mutations, translations, etc.), pathol-
ogy, state-of-the-art imaging (including guidance techniques), blood
tests, drugs/hormones, improved radiotherapy planning systems,
dose, fractionation, radiation type, and, in the near future, radiogenomic
data [4]. Medical decisions should balance cure rate, median survival,
toxicity, comorbidity, quality of life, patient preferences (inform and
involve the patient) and (inmost healthcare systems) cost effectiveness
[5]. This myriad of factors renders clinical decision making a dauntingly
complex, and perhaps inhuman, task as human cognitive capacity is
limited to roughly ﬁve factors per decision [2]. Furthermore, dramatic
genetic [6], epigenetic [7], transcriptomic [8], histological [9] andmicro-
environmental [10] heterogeneity exists within individual tumors,
and even greater heterogeneity exists between patients [11]. In radia-
tion oncology there is heterogeneity in dose prescription, treatment
margins and plan quality (i.e., 3DCRT, IMRT, VMAT, etc.). Moreover,
there is a growing availability of targeted agents and immunotherapy
which also may affect outcome. Despite these enormous complexities,
individualized cancer therapy is realizable. Indeed, intra- and inter-
tumoral variability can be potentially exploited advantageously tomax-
imize the therapeutic ratio, i.e. increasing the effects of therapy upon the
tumor while decreasing those effects on healthy tissues [12–14].
The principal challenge is how best to collect and integrate diverse
multimodal data sources (clinical, treatment, imaging, biological/genet-
ic, etc.) in a quantitative fashion that can provide speciﬁc clinical predic-
tions that accurately and robustly estimate outcomes as a function of
the possible decisions [15,16]. Presently, numerous published predic-
tionmodels are available that account for factors related to both disease
and treatment, but lack standardized evaluation of their robustness, re-
producibility and/or clinical utility [17]. Consequently, these models
may not be suitable (let alone optimal) for clinical decision support
systems.
In this position paper we highlight the recent advances in decision
support systems (DSS) for personalized radiation oncology, with a
focus on the methodological aspects of prediction model develop-
ment/validation aswell as the sophisticated and innovative information
technologieswhich are fundamental to the implementation and successof DSS. The beneﬁts and accompanying challenges of DSS are also
discussed as well as the steps required for the continued progression
and wide spread acceptance of DSS within the clinic.
2. Rapid learning healthcare
2.1. The four phases of rapid learning healthcare
Rapid learning health care (RLHC) [2] (also known as: knowledge-
driven medicine, computer assisted theragnostics, intelligent medical
networks, etc.) is the (re)use of medical data (from both standard clin-
ical practice and clinical trials) to aid in decisionmakingwith respect to
new patients and/or to investigate novel hypotheses [18–22] (Fig. 1a).
RLHC is comprised of four sequential inﬁnitely reiterated phases [2]
(Fig. 1b) that culminates in model development/validation which can
be clinically implemented through DSS [23] (Fig. 1c). The Data phase
handles the attainment and mining of prior data (e.g., patient, disease,
treatment, outcome, etc.). The Knowledge phase utilizes sophisticated
analytical methods, (e.g., machine learning), to harness knowledge
from the aggregated data. The Application phase exploits this knowl-
edge to improve clinical practice. The Evaluation phase assesses DSS
performance with respect to outcomes, subsequently the initial phase
commences once more. For each phase, current best practice coupled
with the latest scientiﬁc understanding is used to optimize the process.
The sections below describe each phase in detail.
2.2. The ‘4 Vs’ of ‘Big Data’
Perfect RLHC demands the ‘4 Vs’ of ‘Big Data’; veracity, velocity, vari-
ety, and volume of data (http://www.ibmbigdatahub.com/infographic/
four-vs-big-data). The veracity of data is critical to the amount of trust
that can be placed in the knowledge acquired. The velocity of data is es-
sential to guarantee that knowledge is gathered as continuously and
constantly as practicable. The variety of data (predominantly with re-
spect to treatmentmodalities aswell as patient and disease characteris-
tics) is fundamental to ultimately conclude which treatment is optimal
for an individual patient. The volume of data is key: A) to obtain en-
hanced knowledge (the ﬁdelity of knowledge is directly related to the
number of patients upon which that knowledge is founded); and B) to
gain knowledge regarding rarer, less heterogeneous patient cohorts
and/or to increase the number of variables in the knowledge phase.
Accessing data with adequate ﬁdelity in relation to the ‘4 Vs’ is the
largest obstacle in RLHC. It is recognized that both the clinical and
research communities need to embrace a data sharing ethos [24],
traversing institutional and national boundaries, so as to realize this
goal [25]. One initiative to accomplish this goal is CancerLinQ [26]
(http://cancerlinq.org/), of the American Society of Clinical Oncology
(ASCO). It is a RLHC system designed to monitor, coordinate, and
improve the quality of care provided to patients with cancer through
the collection, aggregation, and analysis of data extracted from the elec-
tronic health records (EHRs) and practice management systems at
Fig. 1. Overview of the methodological aspects of clinical DSS development/validation, including assessment of clinical utility.
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speciﬁed data elements from a deﬁned cohort, CancerLinQ collects the
complete EHR of all patients in a participating practice. This necessitates
an established secure connection to CancerLinQ from the EHRs and
practice management systems, to periodically transfer a range of infor-
mation. The data proposed to be transferred includes; provider and
patient demographics, appointments, billing codes, patient visit/en-
counter details, medical history and physical examination, family and
social histories, consult reports, surgery reports, pathology and labora-
tory data, and medication administration and prescription history.
Through the use of natural language processing, CancerLinQ will
also be able to collect and process information from clinician notes.
This traditional data centralization approach faces the following
classical barriers to data sharing [27], which come in the form of:
human resources or insufﬁcient time; cultural and language difﬁcul-
ties along with data recording methods; the political and academic
worth of data; hazards to reputation; legal and privacy issue, etc.
These are all signiﬁcant issues to address and are not easily
overcome. However, a cooperative endeavor linking radiotherapy
institutes in the Netherlands, Germany and Belgium (Fig. 2: now
extended to the UK, Italy, Denmark, Australia, China, India, and the
USA — Canada, South Africa and Ireland are currently prospective
partners) successfully realized RLHC through a novel data federated
approach in the euroCAT project (www.eurocat.info, please see the
animation: http://youtu.be/ZDJFOxpwqEA). Novel applications for
advanced information communication technologies were central to
the realization of the endeavor (Fig. 3), facilitating synchronized
RLHC in each center without any data needing to leave the institu-
tion (thus overcoming the classical barriers to data sharing
aforementioned), known as ‘distributed learning’ (please see the
animation: https://www.youtube.com/watch?v=nQpqMIuHyOk).
This forced the development of data with semantic interoperability(also called ‘data with linguistic unity’ or ‘machine-readable data’),
wherein local terms are matched to concepts from awell-deﬁned on-
tology (e.g. NCI Thesaurus). Utilizing this technique, the ontology
terms function as a common interface for the data at each institu-
tional site, allowing a uniﬁed process for information retrieval and
reasoning facilitated by a semantic gateway to the data. An advan-
tage of such initiatives is that they encourage harmonization with re-
gard to what data necessities collection and how (i.e., disease speciﬁc
‘umbrella’ protocols: NCT01855191 https://www.cancerdata.org/
protocols/eurocat-umbrella-protocol-nsclc) [28].2.3. Knowledge
Machine learning is a method to transform data into knowledge. In
machine learning, models/algorithms are utilized to optimally charac-
terize data and generate knowledge which can be exploited to make
predictions with respect to new, unobserved data. Models trained on
past data can be employed to predict the outcomes (e.g., control, toxic-
ity, quality of life, etc.) of numerous treatments using data from a new
patient. With evermore patient characteristics becoming available
(clinical, treatment, imaging, biological/genetic, etc.) there is more
heterogeneity in the data and consequently greater opportunity to
garner superior knowledge. However, an un-validatedmodel is of high-
ly limitedworth and it is thus essential thatmodels are properly validat-
ed. The TRIPOD (transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis) statement is an excellent
template for this— exemplifying increasedmodel accuracy and robust-
ness stemming from proper data management [29–33]; Therefore, a
validation dataset must be readily obtainable, if possible from an exter-
nal institute(s) dissimilar (but not inappropriately different) than that
from which the data was used to train the model.
Fig. 2. Overview of the current ‘worldCAT’ network: Active and prospective partner sites.
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and routine clinical care data) are available for non-small cell lung, rec-
tal and head-and-neck cancer on http://www.predictcancer.org, breast
cancer on http://research.nki.nl/ibr/, prostate cancer on https://www.
mskcc.org/nomograms/prostate, and glioblastoma on http://www.
eortc.be/tools/gbmcalculator/.
2.4. Application
Clinical trials are vital in informing routine clinical care; however,
current designs have considerable deﬁciencies, such as selection bias
(e.g. under-representation of elderly patients) [34–37]. RLHC helps
meet this challenge as the knowledge gained from RLHC is drawn
directly from the routine clinical care population. This knowledge is ap-
plied with the aid of DSS. These are archetypally software applications
that may be utilized to apply RLHC in practice. Examples include nomo-
grams (Fig. 4) [38–40], recursive partitioning analysis models [41],
and websites, such as those given above. DSS are proposed to sup-
port the physician and the patient in taking the most knowledge-
able decision possible with respect to treatment options (they are
neither proposed nor appropriate as a substitute to the physician).
Healthcare professionals leveraging computer models in radiation
oncology are not novel. Physics-based models for dose calculation
along with radiobiology-based normal tissue complication proba-
bility (NTCP) [42] and tumor control probability (TCP) [43] models
to link dose with toxicity and tumor control, are all accepted within
the radiotherapy community. The emergent models from RLHC
[44] are a natural evolution of this practice. An important attribute
of RLHC models is their ‘holistic’ and multifactorial structure, inte-
grating the current physics- and/or radiobiology-based models,along with accounting for patient, tumor and non-radiotherapy
factors [23]. For instance, a RLHC model of radiation-induced
esophagitis predicts that the risk for this toxicity depends not sim-
ply on just the dose to which the esophagus is exposed, but also
signiﬁcantly increases if concomitant chemotherapy is delivered
[45]. Another example is that for non-metastatic unresectable
non-small cell lung carcinoma, the prognostic value in relation to
survival is inferiorly predicted by tumor-node-metastasis (TNM)
classiﬁcation than a multifactorial model built upon clinical, imag-
ing and biomarkers variables [46].2.5. Evaluation
The primary idea in RLHC is that the utilization of knowledge obtain-
ed from clinical data results in comprehensive understanding and sub-
sequently improved predictability of treatment outcomes, suggesting
that these outcomes can be improved both in terms of effectiveness
(attaining the desired outcome) and efﬁciency (the resources needed
to attain the outcome). While adding features may result in enhanced
outcome prediction, this is not always the case and therefore critical
appraisal of complex multifactorial models with comparatively simple
generally accepted models is crucial to deﬁne the precise worth
of added features [32]. Indeed, RLHC models ought to be repeatedly
(re-)evaluated, ﬁxed on the questions ‘Is the outcome of treatment as
expected, and if so, how does this relate to consensus and/or evidence
based guideline knowledge?’. This appraisal ought to if possible be per-
formed with (meta-analysis of) robust data that is independently
interpreted by multiple interested stakeholders (researchers, physi-
cians, economists and patients/representatives).
Fig. 3. Overview of data sources, ﬂow and external access of the current network infrastructure installed at each partner site within ‘worldCAT’.
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3.1. Factors for prediction
The primary goal of producing DSS is to discover, based upon the
available information, a combination of factors that accurately and
robustly predict an individual patient's outcome [47] (e.g., clinical, treat-
ment, imaging, biological/genetic, etc.). Outcomes can be categorized
coarsely as either control (rates of local recurrence, evolution to meta-
static disease, overall survival, etc.) or toxicity (acute, late, moderate,
severe toxicity induction, etc.), or a combination of these end points
(cost effectiveness can also be considered [48]). Although predictive
factors (i.e., factors that inﬂuence response to certain treatments) are
essential for DSS, prognostic factors (i.e., factors that inﬂuence response
without treatment) [49] are equally signiﬁcant in illuminating the com-
plex relationship with outcome. Henceforth, we refer to both of theseterms commonly as ‘features’ because for a predictivemodel correlation
with outcome must be demonstrable.
3.2. Model development
The process of feature selection for model development is compara-
ble to that of biomarker assays [50]. In that framework, we can distin-
guish qualiﬁcation and validation. Qualiﬁcation demonstrates that the
data is predictive of an end point, while validation establishes that a
combination of features is both reliable and suitable for the envisioned
purpose. i.e., features must be identiﬁed and tested in independent
datasets to determine if treatment decisions made based upon these
features would improve outcomes. The complete cycle of model devel-
opment entails several stages (Fig. 1c).
In the hypothesis-generation stage, the end point to predict must be
considered along with the timing of the treatment decision and the
Fig. 4. A nomogram for prediction of 2 year overall survival for stage III non small cell lung cancer patients treated with (chemo) radiotherapy (http://www.predictcancer.org/Main.php?
page=LungSurvivalModel3).
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possible features is performed, by either expert panel or bymathematical
approaches such as a Bayesian network (which has been shown to be su-
perior to expert panels [51]). Sample-size calculations are recommended,
particularly for the validation phase [52,53]. Data from both clinical trials
(high quality, low quantity, controlled/biased selection) and clinical
practice (low quality, high quantity, uncontrolled/unbiased selection)
are useful, however selection biases should be accounted for in both
instances and inclusion criteria ought to be equivalent. For all features,
data heterogeneity is a key requirement to identify predictive features
which enable the personalization of treatment.
Preprocessingmanages various issues such asmissing data (imputa-
tion) [54], incorrectly measured or entered data (sanity checks) [55] as
well as discretizing and normalizing data (if applicable) to avoid sensi-
tivity for different orders of data scales [56]. If an external, independent
dataset is not available for validation, the available datamust be split (in
a separate stage) into a model training dataset and a validation dataset.
In the feature selection stage, the ratio of the number of evaluated fea-
tures to number of outcome events must be kept as low as possible to
avoid overﬁtting [57–59]. When a model is overﬁtted, it is speciﬁcally
and exclusively trained for the training data (including its data noise)
and consequently performs poorly on new data. Data-driven preselection
of features is therefore recommended [60]. Univariate analyses are com-
monly used to prioritize the features— that is, testing each feature individ-
ually and ranking them on their strength of correlation with outcome.
Next, performance measures for the model are determined on both the
training and validation datasets. These measures are typically the area
under the receiver operating characteristic curve (AUC) or the c-index
for censored data [32]. The AUC and c-index quantify the sensitivity and
speciﬁcity of themodel andhave values between0 and 1 (with 1denoting
a perfect model, 0.5 randomness, and 0 the inverse of a perfect model).
3.3. Predicting outcomes
Training data is employed to train a model, classifying all potential
outcomes. Classical statistical [61] as well as machine-learning models
[62] can be considered. For two or more classes (e.g., survival vs
death), logistic regression, support vector machines, decision trees,
Bayesian networks or Naive Bayes algorithms can all be utilized [63,64]. For time-to-event outcomes (irrespective of censorship), Cox pro-
portional hazards models or the Fine and Graymodel [65] of competing
risks are typical. Model selection is dependent on the nature of the
outcome (e.g., logistic regression for two or more outcomes, or Cox re-
gression for survival-type data) and the nature of the training data
(e.g., Bayesian networks necessitate categorized data, while support-
vector machines are appropriate for continuous data). As a general
rule, several models should be evaluated to ascertain which model is
optimal for the available data. This also includes investigation of non-
linear associations and interactions. Akaike's information criterion can
be used to deal with the trade-off between goodness of ﬁt and model
complexity [66] (i.e., a simpler model is expected to be more robust
than a more complex model to a wider range of data).
Performance in the training dataset is always upwards-biased be-
cause the features were selected from the training dataset. Therefore,
a validation dataset is essential to establish the likely performance in
the clinic. Preferably, validation data should come from an external in-
dependent institution or trial. When data is scarce, internal validation
can be conducted using random split, temporal split or k-fold cross-
validation techniques [67]. The developed model should demonstrate
a clear beneﬁt with respect to decision making, and must be evaluated
prospectively in the clinic in the penultimate stage of model develop-
ment. Predictions forecast by the model and clinicians must be com-
pared [45,68] along with standard prognostic and predictive factors
[69]. Application of models in clinical practice often requires an extra
step in the development process.While mostmodels provide a predict-
ed probability for an outcome, clinical decision making usually relies on
threshold values for treatment choices. Depending on the consequences
a threshold value is chosen to minimize either false positives or false
negatives. So a wide range of tools exist, ranging from informative, by
providing a probability, to prescriptive tools, that use a ﬁxed threshold,
and even tools that are capable of identifying patient-speciﬁc thresh-
olds. Irrespective of their nature, it is crucial to conﬁrm improvements
in patient outcome, quality of life and/or reduced toxicity [70], by
performing clinical trials and impact studies whereby the random allo-
cation of patients is predicated by the model. Satisfying this requisite
will produce the ultimate evidence that the model is enhancing health
care by comparing, in a controlled way, the personalized therapy with
standard therapy in the clinic.
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lished, allowing the broader oncological community to assess them.
Full transparency of the data aswell asmethodology is vital to the global
implementation of the model within DSS. This proposition is analogous
to clinical ‘omics’ publications for which the raw data, the code used to
analyze the data, evidence for data provenance (the procedure that led
to a piece of data) and a written report of nonscriptable analysis steps
are customarily made available [71].
3.4. Clinical features
Decision making in radiotherapy is largely built on clinical features,
such as the patient performance status, organ function and grade of
the cancer based on histologic assessment, the extent of the tumor
(deﬁned by the TNM system), age, comorbidity of the patient, etc.
Such features have been repeatedly found to be prognostic for survival
and toxicity [72,73]. Accordingly, such features should be assessed/in-
corporated when developing robust and clinically acceptable models
for DSS. Measurement of some clinical features can be captured with
minimal effort (e.g., performance status). Even a simple questionnaire
should be validated as is the case for laboratory measurements of
organ function or parameters measured from blood [74,75].
A standardized protocol should be established (e.g., the ‘Umbrel-
la’ protocol NCT01855191 https://www.cancerdata.org/protocols/
eurocat-umbrella-protocol-nsclc [28]) to guarantee that compari-
sons are possible and appropriate between centers and question-
naires over time [76]. Additionally, why particular features were
selected for measurement should be clearly explained (e.g., if hemo-
globin measurements were only recorded for patients with fatigue,
the subsequent bias would dictate caution when including and
interpreting the measurements). Only when clinical parameters are
recorded prospectively with a level of scrutiny equivalent to labora-
tory measurements will observational studies become as trustwor-
thy as randomized trials [77,78].
Toxicity measurements and grading should also be based upon vali-
dated systems, such as the common terminology criteria for adverse
events (CTCAE: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-
06-14_QuickReference_5x7.pdf) [79], which can be reported by the
physician or patient [80,81]. Indeed, a recent meta-analysis revealed
that high-quality toxicity assessments from observational trials are
comparable to those of randomized trials [82,83]. However, a prospec-
tive protocol must clarify which system was used and how changes in
toxicity grade over time with respect to treatment were managed.
Finally, to ensure standardized interpretation, the reporting of
clinical and toxicity data and their analyses should be conducted in
line with the STROBE (strengthening the reporting of observational
studies in epidemiology) statement for observational studies and
genetic-association studies, which is essentially a checklist of itemsFig. 5. Example of the variety of dose distributions (calculated on the same patient for severa
oncology for the treatment of prostate cancer. The number following IMRT-3/5/7 refers to thethat should be addressed in reports to simplify critical appraisal
and interpretation of these type of studies [84–86].
3.5. Treatment features
A delicate balance exists between tumor control and treatment-
related toxicity. Presently, image-guided radiotherapy (IGRT) is a highly
precise cancer treatment modality in delivering its agent (radiation) to
the tumor [87]. Additionally, broad knowledge of the effects of radiation
upon normal tissue has been obtained [88–90]. Utilizing modern radio-
therapy techniques – such as Brachytherapy (low dose or High dose
rate), intensity-modulated radiotherapy (IMRT), volumetric arc therapy
(VMAT) or particle-beam therapy – the treatment dose can be sculpted
around the target volumewith dosimetric accuracy of a few percentage
points delivering millimeter precision to spare as much as possible the
organs at risk [91] (Fig. 5).
For modeling purposes, features that are derived from planned spa-
tial and temporal dose distributions are signiﬁcant. Furthermore, a de-
scription of the efforts undertaken during treatment to safeguard that
the prescribed dose is in fact delivered as planned (e.g., in-vivo dosime-
try) is also required [92]. Additional therapies, such as hormonal thera-
py, chemotherapy, targeted agents and surgery, and their respective
features must also be detailed because these also inﬂuence to varying
degrees outcome. A prime example of this is concurrent versus sequen-
tial chemoradiation,which has amajor impact on the incidence of acute
esophagitis and induces dysphagia [93].
With respect to the spatial dimension of radiotherapy, how to
combine information about the spatially variable dose distribution
for every subvolume of the tumor or organ remains an open ques-
tion. Dose–response relationships for tumor and healthy tissues are
frequently reported as mean dose, though voxel-based measures
have also been reported [94]. Mean doses or point doses (e.g., max/
min dose) inside the tumor or healthy tissue are easily quantiﬁed
and are sufﬁcient for numerous applications. However, spatial char-
acteristics might be more relevant in personalized approaches to en-
sure radioresistant/sensitive areas of the tumor or healthy tissue
receive higher/lower doses [95].
Clinical dose volume histogram analysis was ﬁrst described in 1991
for radiation pneumonitis and proctitis after treatments for non-small-
cell lung and prostate cancers [96]. In 2010, a series of comprehensive
reviews of all commonly irradiated organs (the QUANTEC project)
was published [89], illustrating that, similar to the tumor, care must
be taken when assessing dose at the organ level. For example, in some
organs the volume receiving a certain dose is important (such as the
esophagus or lung [97,98]), while in other organs it is the maximum
dose which is most important (such as for the spinal cord [99]).
Predicting toxicity in healthy tissues is an active research area with on-
going, large, prospective multicenter studies [100–107].l established external beam treatment modalities) which are available within radiation
number of beams.
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advised due to the large variability in toxicity which patients' exhibit.
The cause of this variability includes several recognized clinical and
biological/genetic-based features as well as the quality of the treatment
execution (i.e., planned vs delivered dose [108]). The overemphasis on
the planned radiotherapy dose distribution as the primary factor of out-
come is possibly the most common hazard in prediction modeling as
substantial deviations from the original plan during treatment often
occur [109]. The accuracy of predictionmodels is anticipated to improve
whenmeasured dose is used, as this quantity reveals the effect of radio-
therapy most truthfully. Delivered dose reconstructions (2D and 3D
[110]), Gamma-Index calculations and dose volume histograms (DVH)
aid identiﬁcation of increasingly accurate dose-related features [111,
112], such as radiation pneumonitis and esophagitis [98,113].
When considering dose as a treatment feature, it is important to be
aware of the concept of biologically effective dose (BED) [114,115].
The BED concept is an inherent part of the linear quadratic (LQ) model
which is derived from sound biophysical principles of radiation effect
[116], with the consequence that BED is accurate and robust in a reason-
ably wide range of scenarios and can be expressed as:
BED ¼ nd 1þ dα=β
 !
where α and β are the radiosensitivity coefﬁcients associated with le-
thal (linear) cell damage and potentially lethal/repairable (quadratic)
cell damage respectively, n the number of fractions and d the dose per
fraction, such that the total treatment dose is equivalent to nd. BED is
viewed as an important biological measure of the physical dose deliv-
ered to tissue (characterized by theα/β ratio). Therefore, nearby tissues
with differentα/β ratio values (e.g., bladder, prostate, rectum), each re-
ceiving identical dose and fractionation, will be associated with differ-
ent BEDs. It follows that, for a speciﬁed value of the α/β ratio, a
particular BED can be attained by numerous different (yet isoeffective)
fractionation schedules. Thus, BED is a powerful comparator of compet-
ing fractionation schedules. A limitation of this concept is that precise
values for α/β ratios (of both the tumor(s) and healthy tissues) are sel-
dom known in individual patients.
The temporal properties of fractionated treatment are also a vibrant
ﬁeld of research. Treatment dose is rarely increased to compensate for
increases in treatment course duration (especially outside of squamous
cell carcinoma of the head-and-neck or cervix), however, there is a
growing body of evidence which advocates that reduced treatment
times, while delivering the same total dose, improve outcome [117,
118]. A multicenter head-and-neck cancer study of patients treated
with radiotherapy alone showed that the potential doubling time of
the tumor prior to treatment was not predictive of local control [119].
Classic processes such as accelerated repopulation [120], ﬂuctuations
in cell loss, hypoxia and radioresistant tumor stem cells have each
been advocated as the principal origins of this observation, the potential
implications of which include shorter overall treatment times with in-
creased doses per fraction and the avoidance of treatment gaps [121,
122]. Generally, treatment time is an available feature that is associated
with local failure in numerous tumor sites [123–125].
In the ideal scenario, both the spatial and temporal properties of
radiotherapy would be leveraged by monitoring/knowing the cumu-
lative/fractional dose distribution in a tumor and/or healthy tissue
(i.e., a radioresistance/sensitivity map that is continuously updated
during treatment). Regrettably, such a comprehensive maps of
radioresistance/sensitivity do not yet exist, although progress is
being made [126,127]. With the provision of such a map, DSS
would support the planning and adaptation of the spatial and tem-
poral dose distribution in such a manner as to conserve or improve
the therapeutic ratio continuously during treatment, as opposed to
the present method that attempts to deliver the dose to the tumoras planned. Currently, a randomized phase II trial (RTOG 1106/
ACRIN 6697) of individualized adaptive radiotherapy using during-
treatment 18F-ﬂuorodeoxyglucose (FDG)–positron emission tomog-
raphy (PET)/computed tomography (CT) and modern technology in
locally advanced non-small cell lung cancer is underway to answer
important questions with respect to realizing this goal. The hypoth-
esis of the trial is that the during-radiotherapy FDG-PET/CT-based
adaptive therapy will allow increased daily dose to the reduced tar-
get volume for the remainder of the treatment in the majority of pa-
tients and meet the dose limits of organs at risk (OARs), thus
improving loco-regional control without increasing normal tissue
toxicity.3.6. Imaging features: from tumor size to radiomics
Imaging plays a pivotal role in oncology, especially in radiotherapy it
dominates treatment planning and response monitoring roles [128,
129]. Technological progress in imaging – including enhanced temporal
and spatial resolution, faster scanners and protocol standardization –
has rapidly advanced the area towards the identiﬁcation of quantitative
noninvasive imaging biomarkers, also known as “Radiomics”. [21,130,
131] (Fig. 6).
Metrics built on tumor volume and location are the most frequently
employed image derived features of tumor response to therapy and sur-
vival [132–139], and utilize CT or magnetic resonance imaging (MRI)
technology for 3D measurement [140–142]. Although used in clinical
practice, tumor volume and location are subject to inter-observer vari-
ability that can be ascribed to variances in tumor delineations [143,
144]. Furthermore, the optimal techniques formeasurement and deﬁni-
tions of appropriate response criteria are still to be deﬁnitely deter-
mined [145–149]. In addition, tumor motion and image artifacts are
further sources of uncertainty [150,151]. To meet these challenges,
computerized tumor delineation algorithms have been developed
[152–155] based upon image properties such as the range of Hounsﬁeld
units (which characterize the linear attenuation coefﬁcient of the tis-
sue) on the CT which represent a speciﬁc tissue type, or calculation of
the gradient across the CT (mathematical ﬁlter) to reveal the borders
between tissue types. Thorough assessment, however, is required be-
fore these approaches can be routinely used in the clinic [156–158].
A typical tracer for themetabolic uptake of the tumor is FDG for PET
imaging [159,160]. The pretreatment maximum standardized uptake
value (SUV,which is the normalized FDGuptake for an injected dose ac-
cording to the patient’s body weight) is strongly linked with tumor re-
currence as well as overall survival in a number of tumor sites, such as
the lung, head and neck, rectum, esophagus and cervix [161–167]. Addi-
tionally, numerous studies have revealed that variations in SUV during
and after treatment are initial predictors of tumor recurrence [168–
171]. However, FDG-PETmeasurements are dependent on a several fac-
tors, including injected dose, FDG clearance, baseline glucose concentra-
tion, image reconstruction methods used and partial-volume effects
[172,173]. Global standardization of these factors is therefore essential
to enable comparisons and validation of data from FDG-PET imaging
across institutions [174–178].
Multiple studies have demonstrated that diffusion-weighted MRI
parameters, such as the apparent diffusion coefﬁcient (ADC), which
quantiﬁes water mobility in tissues, can accurately predict response
and survival in multiple tumor sites [179–182]. However, issues
concerning reproducibility of ADC measurements – which can be at-
tributed to the dearth of standardization of instrumentation among
vendors and of internationally recognized calibration protocols – re-
main a challenge for these kinds of investigations [183]. Assessments
of varying time points in dynamic contrast-enhanced MRI have also
been employed to quantify tumor perfusion [184–186]. Indeed,
hypothesis-driven preclinical and xenograft studies support these
clinical studies [187–189]. An example of this is that assessment of
Fig. 6. Overview of a radiomics: (a) Tumors are different. Example computed tomography (CT) images of lung cancer patients. CT images with tumor contours left, three-dimensional
visualizations right. Please note strong phenotypic differences that can be captured with routine CT imaging, such as intratumor heterogeneity and tumor shape. (b) Strategy for
extracting radiomics data from images. (I) Experienced physicians contour the tumor areas on all CT slices. (II) Features are extracted from within the deﬁned tumor contours on the
CT images, quantifying tumor intensity, shape, texture and wavelet texture. (III) For the analysis the radiomic features are compared with clinical data and gene-expression data.
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ygenation and lactate level, with tumor control is possible.
Increasingly sophisticated image derived features are presently
being explored. It is currently possible with routine clinical imaging
to capture both tumor heterogeneity and post-treatment changes,
which can be processed to detect functional biomarkers. For in-
stance, a surrogate for tumor perfusion can be directly related be-
tween variations in Hounsﬁeld units in contrast-enhanced CT and
the quantity of contrast agent present in the tissue [190,191] (corre-
sponding perfusion defects can be detected by dual energy CT [192]).
Indeed, decreasing magnitude of CT Hounsﬁeld units after treatment
has been used to assess treatment response in pulmonary, hepatic
and rectal cancers [193,194].
Standardization of image analysis to obtain a large number of fea-
tures derived from imaging is now being considered for novel imaging
biomarker approaches [21] with innovative image processing tech-
niques, descriptors of tumor heterogeneity (such as variance or entropy
of the voxel values) and the relationship of the tumor with adjacent
tissues can be objectively quantiﬁed [195–197]. These systematic
methods facilitate high-throughput assessment of imaging features
which can be correlated with treatment outcome and, potentially,
with biological data [198].
As a proof-of-concept it was shown that underlying genetic changes
and early treatment responses inﬂuenced image derived radiomic
features in a preclinical study [199]. In glioblastoma patients, MR imag-
ing features have strongly corresponded to cancer related and drug
targetable mutational status [200]. Indeed, qualitative imaging features
from CT and MRI images have successfully predicted mRNA abundance
variation in hepatocellular carcinomas and brain tumors [201–203].
Additionally, a composite of anatomical, functional andmetabolic imag-
ing may capture pathophysiological/morphological tumor characteris-
tics in a noninvasive fashion, quantifying intra-tumoral heterogeneity
[204–206].The arrival of radiomics has increased the scope, purpose and
potential for medical imaging within oncology. Radiomics mines
and deciphers numerous medical imaging features. The hypothesis
being that these imaging features are augmented with critical and
interchangeable information regarding tumor phenotype [207].
Additionally, radiomic features provide a complete and full repre-
sentation of the entire tumor and hence adeptly capture intra-
tumor heterogeneity. It is thought that intra-tumor heterogeneity
has potentially profound implications for clinical predictions
(i.e., treatment response, survival outcomes, disease progression,
etc.) and consequently it is deemed to be an essential element of
precision oncology (i.e., a subset of the larger concept of precision
medicine — prevention and treatment strategies that take individ-
ual variability into account) and related research [208–211]. The
concept of precision medicine [212] is not new (e.g., a century of
blood typing to guide blood transfusions), however, the prospect
of applying this concept broadly has been radically enhanced
with the modern development of powerful methods for character-
izing patients, such as radiomics together with large-scale/
interconnected databases and computational tools for analyzing
large complex datasets. Several studies have reported the signiﬁ-
cant predictive/prognostic power of radiomic features. It has
been demonstrated that radiomic features are related to tumor his-
tology, tumor grade/stage, patient survival, metabolism, and sever-
al additional clinical outcomes [213–218]. Furthermore, some
radiogenomic studies have reported the associations between
radiomic features and the underlying gene expression patterns
[219]. Different radiomic features have been evaluated in various
cancer types with respect to diverse imaging technologies [220–
224] and the reproducibility/variability of radiomic features in dis-
parate clinical settings has also been examined [225–227]. These
results suggest that radiomics can enhance individualized treat-
ment selection and monitoring. Furthermore, unlike genomics
Fig. 7. Overview of a simpliﬁed schematic representation of systems biology applied to radiotherapy. a) On the basis of in-vitro, in-vivo and patient data, modules representing the three
biological categories (gene expression, immunohistochemical data and mutation data) important for radiotherapy response can be created. b) For an individual patient, appropriate
molecular data will be accumulated. c) Combining the individual patient data with the modules will provide knowledge on speciﬁc module alterations (such as a deletion,
upregulation [red] or downregulation [blue]), which can be translated to information on relative radioresistance and the molecular ‘weak’ spots of the tumor. This information will
subsequently indicate whether dose escalation is necessary and which targeted drug is most effective for the patient.
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cost effective. Radiomics is an innovative and encouraging break-
through towards the realization of precision oncology.3.7. Biological/genetic features
Biological/genetic features provide valuable biomarkers for DSS
[228–231]; these include prognostic and predictive factors for outcomes
[232], such as tumor response and normal-tissue tolerance. Notwith-
standing these virtues, trials of biological/genetic biomarkers are sus-
ceptible to experimental inconsistency; therefore standardization of
assay criteria, trial design as well as analysis is vital if biological/genetic
biomarkers are to be effective prognostic/predictive tools in oncology
[50] (Fig. 7).Tumor control following treatment is largely determined by the
criteria: the number of cancer stem cells (as often reﬂected by tumor
volume prior to treatment) and their intrinsic radiosensitivity, the hyp-
oxic fraction, repopulation and reoxygenation capacity during the
course of radiotherapy [233–235]. Numerousmethods have beendevel-
oped to quantify the additional features which are predictive of tumor
response.
Tumors exhibit large variability in intrinsic radiosensitivity, in-
cluding among tumors of similar origin and histological type [236–
238]. Efforts to measure the radiosensitivity of human tumors are
currently based upon the ex-vivo tumor survival fraction, detection
of unrepaired DNA double strand breaks, e.g. using phosphorylated
histone γH2AX [239,240]. These investigations have established
that tumor cell radiosensitivity is a major feature for radiotherapy
outcome in prostate, lung, brain, cervical, and head-and-neck
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technical drawbacks which include a low success rate (b70%) for
human tumors and the time required to produce data, which can
be up to several weeks. Studies have shown promising results that
immunohistochemically staining γ-histone H2AX, a marker of DNA
damage, can potentially gauge intrinsic radiosensitivity very early
after commencement of treatment [246,247]. Double-stranded
breaks are produced when cells are exposed to ionizing radiation
or DNA-damaging chemotherapeutic agents, which swiftly results
in the phosphorylation of γ-histone H2AX. γ-Histone H2AX is the
most sensitive marker that can be employed to examine the DNA
damage and its ensuing repair, and it can be identiﬁed by immuno-
blotting and immunostaining using microscopic or ﬂow cytometric
detection. Clinically, two biopsies (prior to and after treatment)
are required to evaluate the γ-histone H2AX status, which can be
difﬁcult to implement in practice.
Previous research has also assessed chromosome damage, DNA
damage, genetic and epigenetic alterations, mitochondrial DNA abnor-
malities, glutathione levels, and apoptosis [248,249]. Indeed, some clin-
ical studies using such assays have demonstrated correlations with
radiotherapy outcome, whereas others have not [250,251]. Despite the
ability to quantify a feature that is fundamental to the response of tu-
mors to radiotherapy, these cell-based functional assays have restricted
clinical utility as a predictive tool.
Hypoxia is the key feature in assessing likely radioresistance and
malignant progression; it is a negative prognostic factor after treatment
with radiotherapy, chemotherapy and surgery [252,253]. Indeed, data
exists which not only demonstrates the requirement of oxygen for
radiation-induced cytotoxic DNA damage or decreased proliferation of
hypoxic cells limiting cytotoxicity of many chemotherapeutic agents
but also suggests that hypoxia stimulates both angiogenesis andmetas-
tasis and therefore plays a crucial role in tumor progression [254].While
a strong correlation has been shown between pimonidazole (a chemical
probe of hypoxia) staining and outcome after radiotherapy in head-
and-neck cancer [255], the same relationship has not been conﬁrmed
in cervical cancer [256]. One hypothesis put forward to reconcile these
contrasting results is that hypoxia tolerance is more important than
hypoxia itself [257].
The use of ﬂuorinated derivatives of such chemical probes also en-
ables their detection by noninvasive PET [258–261]. While this method
does require the administration of a drug, it beneﬁts from sampling the
entire tumor and not just a subvolume of it. An additional potential sur-
rogate marker of tumor hypoxia is vasculature; the predictive worth of
tumor vascularity has been quantiﬁed by both intercapillary distance
(assumed to reﬂect tumor oxygenation) and microvessel density (the
‘hotspot’ technique that offers a histological evaluation of tumor angio-
genesis). Studies have shown positive correlations with outcome –
largely using microvessel density in cervical cancer – although others
have demonstrated negative correlations [262]. Reservations have
been expressed regarding the degree to which biopsies (random sam-
pling of tissue) correctly characterize the typically large, heterogeneous
tumors [263].
When the overall treatment time is protracted, (e.g., equipment
malfunction or poor tolerance by the patient), an increase in the pre-
scription dose is necessary to compensate for the effect of tumor prolif-
eration [264]. While proliferation during fractionated radiotherapy is
evidently a signiﬁcant factor in determining outcome, accurate mea-
surement methods are currently unavailable [265]. A deeper compre-
hension of the response at both the cellular and molecular level is
required alongwith an answer to the question of why radiation induces
accelerated repopulation response in some but not all tumors [266].
Innate differences in cellular radiosensitivity (within the patient
population) govern normal tissue reactions toxicity more than any
other causal factor [267]. The implication being that the majority of
prescribed doses may in fact be too conservative (i.e., because 5–10%
of patients are highly sensitive; they skew what is ‘optimal’ treatmenttowards the lower tier of the tolerance spectrum, to the detriment of
most patients whom are less sensitive). Future DSS should accurately
identify highly sensitive patients and classify them accordingly so they
receive appropriate treatments, facilitating improved/escalated treat-
ments for the less sensitive patients.
Several small and large in vitro studies reported a correlation be-
tween severity of toxicity and radiosensitivity (e.g., radiation-induced
ﬁbrosis of the breast) [268,269], however these studies contain incon-
sistencies due to a lack of standardized quality assurance for in-vivo ra-
diotherapy [270,271]. Corresponding results have also been reported
through rapid assays which quantify chromosomal damage, DNA dam-
age and clonogenic cell survival [272–274]. The lymphocyte apoptosis
assay has beenutilizedwithin a prospective breast cancer trial to stratify
patients and assess late toxicity using letrozole as a radiosensitizer
[275]. Cytokines such as TGF-β, which inﬂuence ﬁbroblast proliferation
and differentiation, are known to play an important role in ﬁbrosis and
senescence [276,277]. However presently, the relationship between late
complications and the lymphocyte predictive assay, TGF-β is strictly
correlative and a mechanistic molecular explanation is missing. Analy-
ses of single nucleotide polymorphisms (SNPs) and genome-wide asso-
ciation studies (GWAS) in candidate genes have demonstrated capacity
in classiﬁcation of normal tissue toxicity [278–284], identifying possible
SNPs associated with the development of late radiation-induced toxici-
ty. Recently, the identiﬁcation of the TANC1 risk allele (SNP rs264663)
suggesting that carriers of this allele have 6 times greater risk of devel-
oping late toxicity, underscores the potential of adding these features to
predictive models. However, validation of SNP or GWAS studies has
turned out to be difﬁcult emphasizing the complex mechanisms behind
radiation-induced toxicity in normal tissue [285,286]. In general, the
weakness of all these approaches has been the large experimental vari-
ability as opposed to the inter-patient variations in radiosensitivity.
Normal tissue toxicity is the dose-limiting factor in the ﬁeld radiation
oncology; therefore, a comprehensive DSS should be built upon predic-
tors of tumor control and normal tissue toxicity.
An additional important and promising development in the ﬁeld of
radiation oncology is that of biomarkers for immunotherapy. It is recog-
nized that ionizing radiation provokes an anti-tumor immune response
and that the clinical potential of these immunogenic effects in combina-
tion with different immunotherapies is substantial [287]. For a durable
and vigorous immune response, activation of T-cells, endowedwith an-
tigen speciﬁcity andmemory effects, is generally a prerequisite [288]. In
such a response several factors are of key importance. Paramount, the
tumor must contain antigens which are different from the healthy
tissue, in order to be recognizable to the immune system. Such neo-
antigens are derived from mutated proteins from a tumor cell. Recent
data shows that the success rate of immunotherapies is dependent on
the presence of neoantigen-speciﬁc T-cells [289]. Consistently, it is
shown that themutational load of a large series of human tumors corre-
lates with the cytolytic activity of natural killer cells and T-cells [290].
When a tumor has the potential to be recognized by the immune
system, an adequate immune response can be orchestrated. In this pro-
cess it is of essential importance that neoantigens are taken up by anti-
gen presenting cells (APCs) or dendritic cells (DCs) and subsequently
cross-presented to naïve T-cells [291]. The latter is then transformed
into tumor killing cytotoxic T-cells. In this context the ability of radiation
to boost immune responses seems to be critically dependent on the
quantity and quality of DCs present [292,293].
Tumors have variable ways to protect them from adequate cyto-
toxic T-cell responses, such as interfering with various immune
checkpoints. Depending on the type of interference several speciﬁc
molecules have biomarker potential. One example of this is the
expression of PD-1L. PD-1L binds PD-1 on the cytotoxic T-cell,
preventing it to conduct its cytolytic action. Regarding the effects
of anti-PD-1 mediated immunotherapy, not only the mutational
load shows a strong correlation with clinical responses but also the
expression of PD-1L in non-small lung cancer patients [294,295].
142 P. Lambin et al. / Advanced Drug Delivery Reviews 109 (2017) 131–153Such biological/genetic features hold great potential and will un-
doubtedly be included in future DSS.
3.8. Visualization of clinical decision support systems
The process of developing a predictive model deﬁnes the character-
istics of the DSS (e.g., features selection, overall prediction accuracy, ro-
bustness, etc.). However, the success/appeal of the DSS depends on
other dynamics, such as its utility, availability, interactivity, adaptability,
etc. which increases the acceptability. Even DSS withmodels developed
in large patient populations, with appropriate external validation, may
fail to be accepted within the health-care community if the DSS is difﬁ-
cult to interpret, if there is little opportunity for application of theDSS or
if the clinical usefulness has not been clearly demonstrated [296].While
some DSS (e.g., decision trees, nomograms, Bayesian networks) funda-
mentally have a visual representation that is readily comprehensible,
many DSS do not. Another method of increasing the acceptability of
DSS for personalized medicine is to make peer-reviewed DSS interac-
tively available online (with sufﬁcient background information); clini-
cians can subsequently scrutinize them using their own patient data.
Such an approach affords retrospective validation of the DSS by the
broader community, as well as providing a gauge of the clinical utility
of the DSS. A website that focuses on DSS for radiotherapy has been
established: www.predictcancer.org. The purpose of this website is to
enable clinicians, researchers, and patients to utilize, develop, and vali-
date the DSS for cancer patients treatedwith radiotherapy. This contrib-
utes to DSS advancement in general by showing the potential and
limitations of these predictions as well as raising awareness
3.9. Cost effectiveness for decision support systems
Traditionally, DSS have been focused on clinical endpoints. However,
considering the almost exponential rising costs of healthcare, it is in-
creasingly important to consider cost and cost-effectiveness in clinicalFig. 8.An illustration of Cost-effectiveness analysis. Comparative effectiveness research is often s
effectiveness. Quality of life in terms of utility scores can be utilized as an outcome measure. T
quantitative estimates of the ﬁnancial impact of therapy and therefore greatly facilitates budgedecision making. Consequently, future DSS should include cost and/or
cost-effectiveness as supplementary endpoints (Fig. 8).
3.10. Shared decision making
DSS can greatly assist in the choice of the most appropriate thera-
peutic and/or diagnostic modality. Yet, deciding the most appropriate
care pathway for each patient is a very complex processwhich is depen-
dent upon unique personal patient characteristics and preferences.
However, hitherto now, DSS do not take patient preferences and per-
sonal values explicitly into account. This stems from the traditional
healthcare approach, which is more paternalistic than participative.
Clinicians may utilize DSS to determine treatment without considering
the distinctive and important personal predilections of patients, as
patients will seldom question or challenge the clinician's opinion.
However recently, this paternalistic approach is more andmore shifting
towards a more participative patient-centered approach. The ramiﬁca-
tions of this shift are that clinicians should proactively provide addition-
al, appropriate, and relevant information to patients thereby realizing
shared decision making (SDM) practice (Fig. 9).
SDM is an interactive process in which patients and practitioners
collaborate in choosing healthcare [297], based upon the best available
evidence [298,299] (e.g., radical or palliative treatment, brachytherapy
or surgery, etc.). Several studies have demonstrated that patients in-
volved decision making, experience less decisional conﬂict, improved
compliancewith treatment and greater quality of life [300]. A signiﬁcant
barrier to the implementation of SDM comes in the form of effective
patient–clinician communication. Clinicians often unintentionally use
difﬁcult language (from the patient's perspective) and may dominate
the conversation, while patients may lack the courage to ask questions.
To involve patients in SDM it is crucial to communicate effectively with
them by providing information and encouraging substantial feedback.
Another important obstacle is that some patients may not be receptive
to the information provided as anxiety or emotional distress can impair
the patient's ability to coherently process information [301]. To helpcarcely available for innovative therapy techniques,making it challenging to examine cost-
he beneﬁt of such analysis is that it provides clinicians, insurers, and policy makers with
ting and allocation of resources.
Fig. 9. Overview of the evolution and development of decision making within medicine. a) Illustrates the conventional dictatorial clinician driven decision making process. b) Displays
progression towards inclusion of patients within the decision making process. c) Demonstrates the advancement of the decision making process to achieve truly personalized and
participative components.
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developed [302,303]. PDAs provide patients with disease-speciﬁc
information and treatment options, through various multimedia,
helping patients to recognize and clarify their personal values
[304–306] (Fig. 10).Fig. 10. An example and overview of an interactive PDA for prostate cancer (http://www.treatm
about which treatment ismost appropriate. The PDA provides information on the available trea
and offers advice based upon the information provided by the patient. It is keenly stressed th
together with the clinician.PDAs do not promote one option over another, nor are they
meant to replace clinician consultation. Instead, they prepare
patients to make informed, values-based decisions with clinicians
(http://ipdas.ohri.ca/). A recent Cochrane review [307] reported
level I evidence that PDAs improve patient's knowledge aboutentchoice.info/). The PDA is intended to assist the patient inmaking an informed decision
tments, helps identify what is important to the patient, compares the available treatments
at the PDA is simply meant to inform the patient, a ﬁnal decision should always be taken
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perceptions. Appropriate SDM within modern medicine requires
the integration of PDAs and DSS. This will genuinely deliver person-
alized and participative therapy that supports both clinicians and
patients.
3.11. An example of personalized therapy in radiation oncology
With deeper knowledge of the complexities of cancer, a realization
that optimal cancer therapy most likely requires increasingly personal-
ized treatment has taken hold. Personalized therapy has huge potential
in cancer care. Within medical oncology the search for personalized
therapy has produced many targeted agents. New medications have
revealed substantial activity within subsets of tumors harboring partic-
ular targetable mutations. Trastuzumab is well recognized for HER2-
positive breast cancer, and recent novel targeted agents such as crizotin-
ib and vemurafenib have been successful in increasing survival in
anaplastic lymphoma kinase rearranged lung cancers and BRAF
(V600E) mutationepositive melanomas, respectively. This underscores
the signiﬁcance of the individual patients' biology, enabling correct
patient and tumor stratiﬁcation. The progress of genetic assays has en-
abled improved prediction of patient sensitivity to different chemother-
apy agents, and there ismounting clinical validation of thesemodels. An
OncotypeDX21-gene assay has been validated to predict both the recur-
rence risk and the magnitude of adjuvant chemotherapy beneﬁt for
breast cancer [308]. However, an OncotypeDX21-gene assay for stage
II colon cancer has been found to be prognostic but not predictive of
an adjuvant chemotherapeutic beneﬁt [309].
The central issues regarding the personalization of radiotherapy are
those of dose, fractionation and target volumes. A type of personalized
therapy is presently ongoing in the form of de-escalating dose for
human papillomavirus positive oropharyngeal cancers. Contrastingly,
considerable research efforts into dose escalation are also underway,
despite negative phase III dose escalation trials for severalmalignancies.
These efforts could be signiﬁcantly augmented by genetic analysis, pro-
viding superior selection of the target population, and therefore increas-
ing the likelihood of success. At the vanguard to personalized therapy
within radiation oncology is the development of a radiation sensitivity
index (RSI), a multigene expression model proposed to predict radia-
tion responsiveness (a high RSI indicates radioresistance) [310–313].
The RSI signature has been previously validated [313], and was recently
applied to primary andmetastatic colon cancer samples [310]. Large dif-
ferences in RSI based on anatomical site of metastases (P b .0001) were
observed, which persisted when the analysis was restricted to lesions
from the same patient (P b .0001). Initial clinical validation in a cohort
of 29 liver and lung metastases patients treated with stereotactic body
radiation therapy conﬁrmed these results [310]. Appreciation of the
strengths and weaknesses of the RSI is essential when evaluating
these results and the implications. The surviving fraction following
2 Gy (SF2) was ascertained in breast, central nervous system, colon,
melanoma, non-small cell lung cancer, ovarian, prostate, renal, and leu-
kemia cell lines [311]. Linear regression analysis correlated ten hub
genes with SF2, and the relative expression of these genes forms the
basis of the RSI. An important point of consideration here is that SF2 ex-
periments are typically conducted under normoxic conditions, dissimi-
larities in local environments of metastatic sites may produce variances
in radiosensitivity undetected in the current assay. Furthermore, the
clinical applicability of the RSI model to differing fractionation regimes
(e.g., hypofractionation) is uncertain. Data supporting clinical validation
of the RSI model is provided in the form of 14 rectal and 12 esophageal
cancer patients treated with neoadjuvant chemoradiation and 92 head
and neck cancer patients treated with deﬁnitive chemoradiation [313].
Potential caveats to accepting this as RSI substantiation include small
cohort sizes and the contribution of concurrent chemotherapy. Addi-
tional data supporting clinical validation of the RSI model is provided
in the form of 503 breast cancer patients, reporting that radiosensitivepatients had improved 5-year relapse free-survival and distantmetasta-
sis free survival rates than radioresistant patients, when treated with
radiotherapy and surgery [312]. Differences in outcome vanished for
(radiosensitive/radioresistant) patients only receiving surgery, suggest-
ing that the RSI is a radiotherapy biomarker. The most recent data
supporting clinical validation of the RSI model is provided by the differ-
ences in radiosensitivity between colon primaries (704 patients) and
sites of metastases (1362 patients), in a further demonstration of the
potential to personalize therapy [310]. RSI ranking by anatomic site re-
vealed large differences: ovary (0.48), abdomen (0.47), liver (0.43),
brain (0.42), lung (0.32), and lymph nodes (0.31); P b .001 (Recall
that a high RSI indicates radioresistance). These results were substanti-
ated in analyses restricted to lesions within the same patient. The con-
clusion being that in the treatment of oligometastatic disease,
prescribed doses should be contingent on the metastatic site, with
lung (the second most frequent site of metastases) being more radio-
sensitive than liver (the most frequent site of metastases). Finally,
data supporting indirect clinical validation of the RSI model is provided
in the form of clinical outcomes for lung (9 patients) and liver (14 pa-
tients) metastases patients (RSI data unavailable) treated with stereo-
tactic body radiotherapy (SBRT) to 60 Gy in 5 fractions. The rate of
2-year local control was noted to be signiﬁcantly higher for lung than
for liver metastases (100% vs 73%, respectively, P = .026). While these
results demonstrate real progress in terms of personalized therapy,
clinical applicability of the RSI model as DSS is hampered by the critical
limitations in both the lack of clinical and treatment characteristics and
the treatment-related outcomes available to correlate with the RSI anal-
ysis and the low patient numbers. These initial results warrant valida-
tion in a larger clinical cohort. Ultimately, notwithstanding these
criticisms, the RSI represents a signiﬁcant and important advance to-
wards further personalizing radiotherapy [314].
3.12. A vision of decision support systems for personalized and participative
radiation oncology in practice
In a clinic two patients diagnosed with non-small cell lung cancer
stage IIIB receive an appointment for a consultation in the same week.
In the year 2010, these two patients would probably have gone through
the same diagnostic procedure receiving identical treatment. With
RLHC these two patients can potentially receive personalized and
participative treatment resulting in two different care paths.
Case A). A 75-year-old male patient has an inoperable squamous cell
carcinoma of the lung stage IIIB. The patient is a heavy smoker and
has limited lung function as well as angina pectoris. His principal wish
is to be able to celebrate, in a reasonable condition, his 40thwedding an-
niversary, which is scheduled to take place in 6 months. Long term sur-
vival is not a priority for him; he does not want to stop smoking and
refuses any heavy treatment which might induce hair loss.
Case B). A 55-year-old female patient, non-smoker, has an adenocarci-
noma of the lung stage IIIB. She is of Asian origin and has 4 children
(between 11 and 18 years). She is a company director and wishes to
be cured at all costs. She insists on the most accurate information on
her prognosis, as she wants to schedule her absence and quality time
with her company and children, respectively. Assuming a fully mature
RLHC network (access to more than 20,000 lung cancer patients' clini-
cal, treatment, imaging, biological/genetic, records as well as a follow-
up data documenting complications and scoring based on the CTCAE
system of the NCI) with integrated DSS and PDAs, the following care
paths are feasible: ﬁrst advanced computer vision and pattern recogni-
tion tools localize, segment and characterize the thorax images (lung,
tumors and heart) of the patients (CT and FDG-PET). Second, DSS aid
in the selection of the most beneﬁcial diagnostic procedure (the most
likely procedure to improve prognosis and/or prediction and/or cost
efﬁciency). Third, DSS with PDAs help the clinician and patient
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ment to achieve the desired survival, toxicity, and/or cost efﬁciency).
Both patients receive a full history/anamnesis, a physical examination,
CT-thorax and a CT-abdomen, a blood sample, and a bronchoscopy
with biopsy. For Cases A) and B) a PET scan with FDG is recommended
by the DSS. After the patients have received a FDG–PET-CT, the DSS
then suggest the following: For Case A) a blood marker for tumor hyp-
oxia, which demonstrates elevated levels. Thus, a PET-CT scan with
FMISO as the tracer for hypoxia is performed which visualizes a limited
zone of hypoxia in 3 cm3within the tumor. For Case B) amutation anal-
ysis of the EGFR gene, a SNP analysis and a gene expression array. The
analyses reveal a mutation of the tyrosine kinase domain of the EGFR,
no polymorphism of the TGF beta gene and a rapidly proliferating
tumor without hypoxia. The missing polymorphism predicts no in-
creased risk for a radiation induced pneumonitis. The DSS suggests a
Thymidine PET-CT scan, enabling visualization of the heterogeneity of
the tumor proliferation, which might suggest a radiation boost of a
sub-volume of the tumor. Before treatment begins the various outcomes
for each treatment, based on the pretreatment prediction module, are
discussed with the patient. Case A) after discussion with his doctor he
decides to accept a high dose radiotherapy treatment including a con-
comitant boost of the hypoxic region within the tumor but refuses the
addition of chemotherapy drugs. The polymorphism analysis of the
TGF beta gene reveals an increased risk for radiation-induced pneumo-
nitis. The DSS therefore advise an early follow-up extensive vaccination
program against inﬂuenza and pneumonia. As a consequence of this
care pathway, the patient decides to move into an apartment on the
ground ﬂoor without stairs. Finally, he and his wife are able to celebrate
their 40th wedding anniversary with no major toxicity. One and a half
years later, the patient passes away due to progressive liver metastases.
Case B) after discussion with her doctor, she agrees to undergo a con-
comitant accelerated chemo-radiotherapy treatment together with the
combined adjuvant treatment of an anti-EGFR drug (due to the positive
EGFRmutation analysis). Twoweeks into treatment, the risk of esopha-
gitis together with weight loss (taking into account neutropenia) is re-
evaluated. Using the pre-treatment DSS it is suggested that the risk for
the development of severe esophagitis is higher than 70%. Consequent-
ly, an esophageal feeding tube is transiently positioned. A second post-
treatment DSS prediction of survival and pneumonitis is than per-
formed which takes into account the quality of treatment (set-up
error, in vivo dosimetry, treatment duration, drug effectively given)
and the metabolic response at 3 months (based on a FDG–PET). In this
particular case, the probability of survival at 2 years is predicted to be
85%. Consequently, the patient decides not to sell her company. The
follow-up DSS identify her case as high risk for the development of
brain metastases and advise either regular repeated brain MRI or pre-
ventive total brain irradiation, which in this case was favored by the pa-
tient. Five years later, the patient remains free of disease. An update of
the system integrating new data on cancer risk and gene polymor-
phisms reveals an increased risk for the development of breast cancer
together with her thorax irradiation. This convinced her to begin yearly
mammography screening.
The above treatments described are not the standard of care and are
hypothetically the optimal treatments with the goal of personalizing
care (e.g., concurrent treatment with an anti-EGFR drug is currently
under investigation (RTOG 1306) and is not routinely performed in all
patients with a mutation.).
4. Future prospects
Enthusiasm for the great potential of the futuremust be tempered by
the pragmatic reality of the present. Currently, most of the ‘eHealth’ an-
alytics effort is focused on monitoring and improving hospital costs,
quality of healthcare management, and productivity. The initial impact
and widespread adoption of RLHC together with DSS will probably befelt ﬁrst in an administrative/business sense rather than a scientiﬁc/
clinical sense within institutions. When RLHC together with DSS even-
tually do make it to the clinical setting, there is the potential risk of
the misuse of such technologies/tools (e.g., generation of artifacts,
false signals, data corruption, etc.). These genuine concerns can be
averted by implementing and adherence to stringent universal data-
quality assurance programs and semantic interoperability harmoniza-
tion, coupled with automated data correction, imputation and/or rejec-
tion procedures.
The need for very complex DSS should be relativized as recently ap-
proved novel anti-cancer therapies, such as immunologics, are yielding
major therapeutic gains which massively outweigh the small gains of
former anti-cancer approaches. Thus the need for complex DSS when
the gains of treatment A versus B differ massively, does not have the
same implication for the decision making process as with classical
4–7% gains.
The primary focus of this position paper has been model develop-
ment/validation forDSS alongwith the cutting-edge information technol-
ogies which are essential for the realization of such DSS. While an
accurate model forms the foundation of a DSS, further concerns must be
addressed prior to a new DSS being utilized in routine clinical practice.
Foremost, all decisions taken by a physician (or patient) can be dis-
tilled into a balance between harm (toxic effects, complications, quality
of life and ﬁnancial cost) and beneﬁt (survival, local control and quality
of life). For instance, larger dose typically results in a greater probability
of normal tissue toxicity, but also a parallel greater probability of tumor
control. Determining the correct balance between harm and beneﬁt is a
profoundly personal choice that varies considerably among patients.
Therefore, an ideal DSS should comprehensively predict local control,
survival, toxicity, quality of life and cost. The DSS should present these
estimates and the balance between them in a manner that is easily
interpreted by both the physician and the patient, enabling shared deci-
sion making.
Furthermore, all predictions made by a DSS must include conﬁ-
dence intervals. Correctly estimating conﬁdence intervals is a
dynamic and challenging ﬁeld of research due to the unique uncer-
tainties associated with the process e.g., feature noise, missing fea-
tures, size and quality of the training dataset, as well as the
inherent uncertainty of cancer; must all be combined to specify the
uncertainty in the prediction for any given individual patient. DSS
are deﬁcient when deprived of certainty with respect to potential
choices that may or may not have a statistically signiﬁcant and/or
clinically meaningful difference in outcome. Distributed learning of
appropriate data upon which the model was developed is a key in-
gredient to achieve sufﬁcient certainty in DSS. Despite the ethical,
administrative, political and technical boundaries, the continuing
development, interconnection, and growth of RLHC networks to-
wards full maturity are of vital importance to modern medicine, as
the future performance of DSS is dependent upon both the number
and heterogeneity of available patients to learn from. However,
there are still difﬁculties to be addressed with regard to distributed
learning within RLHC networks. For example, model developers
cannot access and curate all available data within a RLHC network,
consequently stringent quality assurance protocols coupled with au-
tomated data correction, imputation and/or rejection procedures
need to be developed and standardized.
Notwithstanding these challenges, the dream of accurate robust pa-
tient speciﬁc predictive models leading to DSS that are dynamically
updated through global RLHC networks is becoming an ever increasing-
ly tangible reality, and many important milestones have already been
reached. These include the aforementioned universal data-quality
assurance programs and semantic interoperability harmonization. In-
deed, investment is already underway in research and innovation for
health-informatics systems (Apple, Google, IBM, etc.), which indicates
that ‘eHealth’ will be among the major health-care innovations of the
coming decades.
146 P. Lambin et al. / Advanced Drug Delivery Reviews 109 (2017) 131–153It is our ﬁrm belief that this genuinely innovative approach will lead
to urgently necessary improvements in both healthcare effectiveness
and efﬁciency.
This position paper has thus far focused on the predictive, personal-
ized, and participative elements of medicine, however, medicine will
transition (even farther) from a reactive to a proactive discipline over
the coming decade— a discipline that is predictive, personalized, partic-
ipative and preventive (P4) [315–317]. P4 medicine will be driven by
system approaches to disease/health, utilizing emerging technologies
and analytical tools. Preventive medicine can become a reality as fully
matured RLHC networks expose the opportunity to apply therapies
intended to prevent or halt disease progression. Importantly, invoking
the P4 medicine concept will enable a paradigm-shift in health care
from an emphasis on disease to a focus on health—with vast associated
cost savings for society resulting in a decreased absenteeism fromwork
and a parallel increase in productivity. P4 medicine is a potentially
catalyzing revolution of modern medicine that offers solutions to man-
age the heretofore overwhelmingobstacles of incredible complexities of
disease/health via systems approaches, innovative technologies and
sophisticated analytical tools. The ultimate goal is that the emphasis of
medicine will be lifted from disease and placed onto health. In the not
too distant future, there is the very real possibility that billions of data
points for each individual within fully matured RLHC networks will de-
ﬁne with exquisite exactitude the precise nature of their health — and
any transitions into disease.
5. Conclusions
Truly personalized cancer therapy is the goal in modern oncology.
However, personalized cancer therapy is also a colossal challenge. The
immense diversity of both cancer patients and therapy choices makes
it tremendously problematic to decidewhich choices are best for the in-
dividual patient. Nevertheless, DSS produced by RLHC can contribute to
the realization of this goal. Accurate robust validated predictionmodels
are being swiftly developed, whereby multiple features related to the
patient, disease, and treatment are combined into an integrated predic-
tion. The key, however, is standardization — mainly in data acquisition
across all areas (clinical, treatment, imaging, biological/genetic, etc.).
Standardization requires harmonized clinical guidelines, regulated
image acquisition and analysis parameters, validated biomarker assay
criteria and data-sharing methods that use identical ontologies.
Assessing the clinical utility of any DSS is just as important as standard-
izing the development of externally validated accurate and robust pre-
diction models with high-quality data, preferably by standardizing the
design of clinical trials. These crucial steps are the basis of validating
DSS,which in turn,will stimulate developments in RLHC andwill enable
the next major advances in personalized and participative medicine.
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